Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
G Crișan, NS Moldovean-Cioroianu… - International journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
ImmunoPET: concept, design, and applications
W Wei, ZT Rosenkrans, J Liu, G Huang, QY Luo… - Chemical …, 2020 - ACS Publications
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …
PET imaging in neuro-oncology: An update and overview of a rapidly growing area
Simple Summary Positron emission tomography (PET) is a functional imaging technique
which plays an increasingly important role in the management of brain tumors. Owing …
which plays an increasingly important role in the management of brain tumors. Owing …
Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma
CJ Pachocki, EM Hol - Journal of neuroinflammation, 2022 - Springer
Diffuse midline glioma (DMG), formerly called diffuse intrinsic pontine glioma (DIPG), is a
high-grade malignant pediatric brain tumor with a near-zero survival rate. To date, only …
high-grade malignant pediatric brain tumor with a near-zero survival rate. To date, only …
Current Perspectives on 89Zr-PET Imaging
JK Yoon, BN Park, EK Ryu, YS An, SJ Lee - International Journal of …, 2020 - mdpi.com
89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …
The beginning of the end for conventional RECIST—novel therapies require novel imaging approaches
M Gerwing, K Herrmann, A Helfen… - Nature reviews Clinical …, 2019 - nature.com
Owing to improvements in our understanding of the biological principles of tumour initiation
and progression, a wide variety of novel targeted therapies have been developed …
and progression, a wide variety of novel targeted therapies have been developed …
ImmunoPET: antibody-based PET imaging in solid tumors
Immuno-positron emission tomography (immunoPET) is a molecular imaging modality
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
combining the high sensitivity of PET with the specific targeting ability of monoclonal …
The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals
GAMS van Dongen, W Beaino… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …
have impacted clinical care but have also come with challenges. Such therapeutics include …
Theranostics using antibodies and antibody-related therapeutics
KL Moek, D Giesen, IC Kok, DJA de Groot… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In theranostics, radiolabeled compounds are used to determine a treatment strategy by
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …
Targeted nuclear medicine. Seek and destroy
VM Tolmachev, VI Chernov… - Russian Chemical …, 2022 - iopscience.iop.org
The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …
treatment of malignant neoplasms. The development of scaffold proteins has significantly …